Lexicon Pharmaceuticals stock faces Q3 results before market open
Published on 11/05/2026 at 03:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLexicon prepares third-quarter update
- Lexicon plans to publish its third-quarter 2026 financial results before the US market opens on Thursday.
- Management will provide a business update during an 8:30 a.m. ET conference call.
- The company is developing medicines for cardiometabolic diseases, including hypertrophic cardiomyopathy, type 1 diabetes and obesity.
Lexicon Pharmaceuticals said on October 29 that it will release its third-quarter 2026 financial results before the US market opens on Thursday, November 5. The announcement was carried by GlobeNewswire on behalf of the company.
Results arrive before market open
Management plans to discuss the financial results and provide a business update during a conference call and live webcast at 8:30 a.m. Eastern Time, or 7:30 a.m. Central Time. Lexicon said an archived version of the webcast will be available on its website.
The release places the focus on the company's quarterly performance and its development pipeline. Investors will be watching the update for progress in the programs that support Lexicon's cardiometabolic strategy.
Pipeline targets metabolic diseases
Lexicon describes itself as a biopharmaceutical company developing medicines for serious cardiometabolic diseases. Its pipeline includes programs in hypertrophic cardiomyopathy, type 1 diabetes, obesity and related metabolic conditions.
Lexicon Pharmaceuticals at a glance
- Company: Lexicon Pharmaceuticals, Inc.
- Ticker: LXRX
- ISIN: US5288723027
- Event: Third-quarter 2026 results and business update
- Schedule: Thursday, November 5, before market open; conference call at 8:30 a.m. ET
Investors can follow the broader US market through the S&P 500 market overview.
